SSS supports pilot study for new covid-19 rapid test funded by the Bavarian Ministry of Health
SSS International Clinical Research is supporting a trial, in which the Munich startup company GNA Biosolutions verifies their innovative rapid Covid-19 “GNA-Octea” test. At a press conference at the Munich Airport on Monday, 15th of February 2021, the Bavarian Ministers Hubert Aiwanger (Economy) and Klaus Holetschek (Health) informed about first encouraging results of a pilot study performed currently at three test sites in Bavaria.
Proprietary CTMS System accSIS helps SSS to stand global challenges
The increasing regulatory demands and the globalization of research has made clinical projects more and more demanding in recent years. In nowadays CROs have to handle much more information and interfaces. Starting already 15 years back SSS has developed a company-own Clinical Trial Management System (CTMS) system. Grown to a powerful tool it meets all requirements off full-service clinical projects in a global setting. SSS currently performs projects in 22 countries on three continents. In a recent publication in European Pharmaceutical Contractor from August 2020 we describe how such an integrated system enables mid- size CROs to perform even huge global projects.
SSS will take part as invited speaker at the German Corona Showcase 2021 taking place on April 28th – April 30th, 2021.
SSS will showcase the fast track approval ("Sonderzulassung") at BfArM for the rapid Covid-19 test "Octea" by GNA Biosolutions GmbH. SSS has operated the performance test and the submission to BfArM as responsible CRO.
More about the event organized by Bio Deutschland can be found here
Please do not hesitate to contact us for personal consultations for your needs in clinical projects:
Tel: +49 89 800 650 0
Fax: +49 89 800 650 555